Inomagen Therapeutics Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
Later Stage VC
- Investors
-
4
Inomagen Therapeutics General Information
Description
Developer of a non-viral gene therapy designed to treat the underlying mechanisms of atrial fibrillation. The company offers a proprietary gene delivery system utilising reversible electroporation for targeted, minimally invasive transvenous administration of genetic material to the cardiac atrium, enabling patients to get treatment with various stages of atrial fibrillation by addressing molecular causes and reducing arrhythmia and fibrosis, enabling an alternative to existing therapies that do not target disease origins.
Contact Information
Website
www.inomagen.comCorporate Office
- 400 North Aberdeen Street
- Suite 900
- Chicago, IL 60642
- United States
Corporate Office
- 400 North Aberdeen Street
- Suite 900
- Chicago, IL 60642
- United States
Inomagen Therapeutics Timeline
Inomagen Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 10. Later Stage VC | 03-Sep-2026 | Completed | Pre-Clinical Trials | |||
| 9. Later Stage VC | 19-Jun-2025 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC | 12-Apr-2024 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC | 01-Sep-2022 | Completed | Pre-Clinical Trials | |||
| 6. Grant | 11-Mar-2022 | Completed | Pre-Clinical Trials | |||
| 5. Grant | 01-May-2021 | Completed | Pre-Clinical Trials | |||
| 4. Grant | 14-Apr-2021 | Completed | Pre-Clinical Trials | |||
| 3. Accelerator/Incubator | 15-Dec-2015 | Completed | Startup | |||
| 2. Angel (individual) | 21-Nov-2014 | $200K | $200K | Completed | Startup | |
| 1. University Spin-Out | 01-Jan-2014 | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Inomagen Therapeutics Signals
Inomagen Therapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Portal Innovations | Venture Capital | Minority | ||
| NIH Seed | Not-For-Profit Venture Capital | |||
| National Heart, Lung, and Blood Institute | Government | |||
| National Institutes of Health | Government |
Inomagen Therapeutics FAQs
-
When was Inomagen Therapeutics founded?
Inomagen Therapeutics was founded in 2014.
-
Where is Inomagen Therapeutics headquartered?
Inomagen Therapeutics is headquartered in Chicago, IL.
-
What is the size of Inomagen Therapeutics?
Inomagen Therapeutics has 6 total employees.
-
What industry is Inomagen Therapeutics in?
Inomagen Therapeutics’s primary industry is Drug Discovery.
-
Is Inomagen Therapeutics a private or public company?
Inomagen Therapeutics is a Private company.
-
What is Inomagen Therapeutics’s current revenue?
The current revenue for Inomagen Therapeutics is .
-
How much funding has Inomagen Therapeutics raised over time?
Inomagen Therapeutics has raised $540K.
-
Who are Inomagen Therapeutics’s investors?
Portal Innovations, NIH Seed, National Heart, Lung, and Blood Institute, and National Institutes of Health have invested in Inomagen Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process